STOCK TITAN

Galmed Pharmaceuticals Ltd - GLMD STOCK NEWS

Welcome to our dedicated news page for Galmed Pharmaceuticals (Ticker: GLMD), a resource for investors and traders seeking the latest updates and insights on Galmed Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Galmed Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Galmed Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.53%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.79%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.84%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
Galmed Pharmaceuticals Ltd

Nasdaq:GLMD

GLMD Rankings

GLMD Stock Data

2.52M
5.78M
3.87%
9.44%
0.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
16 Zeev Tyomkin St 4th Fl

About GLMD

galmed pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or fabacs. aramchol is initially being developed for treating non-alcoholic steato-hepatitis, or nash, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. galmed pharmaceuticals galmed’s business has been, in its current legal structure, was incorporated in israel on july 31, 2013 as a privately held company. however, operating since 2000 under a different group of companies established in the same year. galmed was co-founded by professor tuvia gilat and allen baharaff, based on professor gilat’s extensive research in fabac’s and nash.